BLRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
BioLine RX Ltd (BLRX) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock shows weak financial performance, bearish technical indicators, no positive trading signals, and lacks any significant positive catalysts. Additionally, the stock's future trend suggests further downside potential.
The technical indicators for BLRX are bearish. The MACD histogram is negative and expanding downward, RSI is neutral but close to oversold territory, and moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). The stock is trading below key pivot levels, with support at 2.725 and resistance at 2.969. The stock has a 70% chance of declining further in the short term (-2.06% in the next day, -2.75% in the next week, -4.7% in the next month).
No positive catalysts identified. There is no recent news, no insider or hedge fund activity, and no recent congress trading data.
Gross margin has also declined. The stock's implied volatility is extremely high (IV percentile: 98.01, IV rank: 100), indicating uncertainty and potential risk. Additionally, the stock has no recent trading signals (AI Stock Picker or SwingMax) and bearish technical indicators.
In Q3 2025, BioLine RX Ltd reported a significant drop in revenue (-91.36% YoY) to $427,000 and net income (-83.22% YoY) to -$977,000. EPS remained flat at 0, and gross margin declined slightly to 80.33%. Overall, the company's financials show a downward trend, indicating poor growth and profitability.
No data on analyst ratings or price target changes is provided. Wall Street sentiment appears neutral to negative based on the lack of positive catalysts and weak financial performance.
